{"id":708617,"date":"2024-08-02T17:28:01","date_gmt":"2024-08-02T17:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=708617"},"modified":"2024-08-02T17:28:01","modified_gmt":"2024-08-02T17:28:01","slug":"severe-hypertriglyceridemia-pipeline-drugs-2024-arrowhead-pharmaceuticals-ionis-pharmaceuticals-inc-89bio-inc-regeneron-pharmaceuticals-kowa-research-institute-inc-mochida-pharmaceutical","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/severe-hypertriglyceridemia-pipeline-drugs-2024-arrowhead-pharmaceuticals-ionis-pharmaceuticals-inc-89bio-inc-regeneron-pharmaceuticals-kowa-research-institute-inc-mochida-pharmaceutical_708617.html","title":{"rendered":"Severe Hypertriglyceridemia Pipeline Drugs 2024 | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical,"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1722603485.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Severe Hypertriglyceridemia Pipeline Drugs 2024 | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical,\" src=\"https:\/\/www.abnewswire.com\/uploads\/1722603485.jpeg\" alt=\"Severe Hypertriglyceridemia Pipeline Drugs 2024 | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical,\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;Severe Hypertriglyceridemia Pipeline Insight 2024&rdquo;<\/strong>&nbsp;report provides comprehensive insights about&nbsp;<strong>10+ companies and 10+ pipeline drugs<\/strong>&nbsp;in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the latest drugs and treatment options in the Severe Hypertriglyceridemia Pipeline. Dive into DelveInsight&#8217;s comprehensive report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Severe Hypertriglyceridemia Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>August 2024:- Ionis Pharmaceuticals- An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). This is a multi-center, open-label study of up to 700 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen during the 53-week treatment period. The study will include a 31-day qualification Period, a 53-week treatment period, and a 13-week post-treatment period.<\/li>\n<li>DelveInsight&rsquo;s Severe Hypertriglyceridemia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Severe Hypertriglyceridemia treatment.<\/li>\n<li>The leading Severe Hypertriglyceridemia Companies such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others.<\/li>\n<li>Promising Severe Hypertriglyceridemia Therapies such as Olezarsen, Plozasiran Injection, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Stay ahead with the most recent pipeline outlook for Severe Hypertriglyceridemia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Severe Hypertriglyceridemia Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Hypertriglyceridemia Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ARO-APOC3: Arrowhead Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Currently, it is in Phase II stage of clinical trial evaluation to treat Severe Hypertriglyceridemia.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Olezarsen: Ionis Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III in the liver. ApoC-III is a protein that regulates triglyceride metabolism in the blood by inhibiting lipoprotein lipase that breakdown triglycerides and by preventing clearance of triglyceride-rich lipoproteins. ApoC-III is an independent risk factor for both pancreatitis and cardiovascular disease.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Explore groundbreaking therapies and clinical trials in the Severe Hypertriglyceridemia Pipeline. Access DelveInsight&#8217;s detailed report now! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">New Severe Hypertriglyceridemia Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Inhalation<\/li>\n<li>Inhalation\/Intravenous\/Oral<\/li>\n<li>Intranasal<\/li>\n<li>Intravenous<\/li>\n<li>Intravenous\/ Subcutaneous<\/li>\n<li>NA<\/li>\n<li>Oral<\/li>\n<li>Oral\/intranasal\/subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Severe Hypertriglyceridemia Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Antibody<\/li>\n<li>Antisense oligonucleotides<\/li>\n<li>Immunotherapy<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptides<\/li>\n<li>Protein<\/li>\n<li>Recombinant protein<\/li>\n<li>Small molecule<\/li>\n<li>Stem Cell<\/li>\n<li>Vaccine<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Unveil the future of Severe Hypertriglyceridemia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight&#8217;s expert analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Severe Hypertriglyceridemia Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Severe Hypertriglyceridemia Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Severe Hypertriglyceridemia companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others.<\/li>\n<li>Severe Hypertriglyceridemia Therapies such as Olezarsen, Plozasiran Injection, and others.<\/li>\n<li>Severe Hypertriglyceridemia Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Severe Hypertriglyceridemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get the latest on Severe Hypertriglyceridemia Therapies and clinical trials. Download DelveInsight&#8217;s in-depth pipeline report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Severe Hypertriglyceridemia Companies, Key Products and Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Severe Hypertriglyceridemia: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Severe Hypertriglyceridemia &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Olezarsen: Ionis Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>ARO-APOC3: Arrowhead Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Severe Hypertriglyceridemia Key Companies<\/li>\n<li>Severe Hypertriglyceridemia Key Products<\/li>\n<li>Severe Hypertriglyceridemia- Unmet Needs<\/li>\n<li>Severe Hypertriglyceridemia- Market Drivers and Barriers<\/li>\n<li>Severe Hypertriglyceridemia- Future Perspectives and Conclusion<\/li>\n<li>Severe Hypertriglyceridemia Analyst Views<\/li>\n<li>Severe Hypertriglyceridemia Key Companies<\/li>\n<li>Appendix<strong>&nbsp;<\/strong><\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=severe-hypertriglyceridemia-pipeline-drugs-2024-arrowhead-pharmaceuticals-ionis-pharmaceuticals-inc-89bio-inc-regeneron-pharmaceuticals-kowa-research-institute-inc-mochida-pharmaceutical\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=severe-hypertriglyceridemia-pipeline-drugs-2024-arrowhead-pharmaceuticals-ionis-pharmaceuticals-inc-89bio-inc-regeneron-pharmaceuticals-kowa-research-institute-inc-mochida-pharmaceutical\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s,&nbsp;&ldquo;Severe Hypertriglyceridemia Pipeline Insight 2024&rdquo;&nbsp;report provides comprehensive insights about&nbsp;10+ companies and 10+ pipeline drugs&nbsp;in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/severe-hypertriglyceridemia-pipeline-drugs-2024-arrowhead-pharmaceuticals-ionis-pharmaceuticals-inc-89bio-inc-regeneron-pharmaceuticals-kowa-research-institute-inc-mochida-pharmaceutical_708617.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-708617","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/708617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=708617"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/708617\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=708617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=708617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=708617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}